BioCardia, Inc. 8K

BioCardia, Inc. announced second quarter 2026 financial results and business updates, highlighting regulatory progress for its cardiovascular therapies, ongoing clinical trial enrollment, platform development, reduced net loss, and additional capital raised via its at-the-market facility.

On August 12, 2026, BioCardia, Inc. reported its financial results and business highlights for the second quarter ended June 30, 2026, noting progress in regulatory interactions for its CardiAMP cell therapy and Helix delivery system in Japan and the United States, continued enrollment in its CardiAMP HF II trial, advancement of its Heart3D imaging platform, and improved operating results including reduced research and development expenses, a smaller net loss, approximately $4.9 million raised under its at-the-market equity facility, and quarter-end cash and cash equivalents of $4.1 million providing expected runway into 2027.

Filing Facts

CIK

925741

Ticker

-

Form

8K

Source Type

sec

Accession

0001437749-26-027332

Alert Tier

6